ESCRS - PO277 - Risk Factor Analysis And Efficacy Of Topical Voriconazole Monotherapy In Treatment Of Microsporidial Keratoconjunctivitis

Risk Factor Analysis And Efficacy Of Topical Voriconazole Monotherapy In Treatment Of Microsporidial Keratoconjunctivitis

Published 2022 - 40th Congress of the ESCRS

Reference: PO277 | Type: ESCRS 2022 - Posters | DOI: 10.82333/x48v-b246

Authors: Pallavi Dhawan 1 , Lional Raj* 2

1ophthalmology,Dr Agarwal's Eye Hospital,Chennai,India, 2Cataract, Cornea and Refractive Surgery,DR AGARWALS EYE HOSPITALS,Chennai,India

Purpose

To study the risk factors and  efficacy of  topical voriconazole 1% in microsporidial keratoconjunctivitis.

Setting

Tertiary eye care centre

Methods

A case series of forty patients of microsporidial keratoconjunctivitis presented over a year in cornea clinic of a tertiary eye care studied prospectively for clinical outcome,risk factors and efficacy of topical voriconazole 1%

Results

The age group of patients is from 15 to 56 years.Male preponderence is noted.Most patients (83.5%) presented just after the monsoon. 10 (25%) patients gave history of fall of dust particles and 8 (20%) gave history of exposure of rain water.Systemic history revealed 4 (10%) patients had history of loose motions in recent past.All patients were negative on HIV investigation.All patients were scraped and microbiological testing done.All patients started with topical voriconazole 1% and they responded well to it.Mean duration of resolution was 2 weeks.Out of 40,38 patients responded well without sequelae.Out of 2 patients,one developed sub epithelial opacity and other ild iritis.

Conclusions

Most cases of microsporidial keratoconjunctivitis present after the onset of local monsoon.Its common in immunocompetent population.Superficial punctate keratitis in microsporidial keratoconjunctivitis responds well to topical voriconazole  monotherapy.